XML 53 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Statements of Operations-Additional Information (Tables)

12 Months Ended

Jun. 30, 2024

Statements of Operations-Additional Information

Schedule of revenues disaggregated by major product category and geographic region

Net Sales by Product Type

​	​	​	​	​	​	​	​	​	​
​		​		​	​		​	​
For the Year Ended June 30	​	2024		​	2023		​	2022
Animal Health	​	​			​		​	​	​
MFAs and other	​	$	420,959	​	$	387,349	​	$	361,538
Nutritional specialties	​		164,671	​		172,504	​	​	157,196
Vaccines	​		120,852	​		99,998	​	​	88,321
Total Animal Health	​	$	706,482	​	$	659,851	​	$	607,055
Mineral Nutrition	​		243,663	​		242,656	​	​	259,512
Performance Products	​		67,534	​		75,382	​	​	75,694
Total	​	$	1,017,679	​	$	977,889	​	$	942,261

​

Net Sales by Region

​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​
For the Year Ended June 30	​	2024			2023			2022
United States	​	$	584,763	​	$	578,773	​	$	561,803
Latin America and Canada	​		247,705	​		219,846	​	​	191,047
Europe, Middle East and Africa	​		121,977	​		117,815	​	​	122,480
Asia Pacific	​		63,234	​		61,455	​	​	66,931
Total	​	$	1,017,679	​	$	977,889	​	$	942,261

Schedule of interest expense, net

​

​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​
For the Year Ended June 30	​	2024			2023			2022
Interest expense, net	​	​	​	​	​	​	​	​	​
2021 Credit Facilities	​	$	20,646	​	$	17,302	​	$	11,918
2022 Term loan	​	​	862	​	​	589	​	​	—
Amortization of debt issuance costs	​		1,040	​		727	​		590
Other	​		462	​		58	​		183
Interest expense	​		23,010	​		18,676	​		12,691
Interest income	​		(4,474)	​		(3,355)	​		(816)
​	​	$	18,536	​	$	15,321	​	$	11,875

Schedule of depreciation and amortization

​

​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​
For the Year Ended June 30		2024			2023			2022
Depreciation and amortization	​		​	​		​	​
Depreciation of property, plant and equipment	​	$	26,517	​	$	24,316	​	$	23,781
Amortization of intangible assets	​		9,661	​		9,696	​		8,924
​	​	$	36,178	​	$	34,012	​	$	32,705

Schedule of amortization of intangible assets

​

​	​	​	​
For the Years Ending June 30		​
2025	​	$	7,918
2026	​		6,969
2027	​		6,591
2028	​		6,385
2029	​		6,385
Thereafter	​		10,785
Total	​	$	45,033

Schedule of research and development expense

​

​	​	​	​	​	​	​	​	​	​
For the Year Ended June 30		2024			2023			2022
Research and development expense	​	$	29,194	​	$	24,395	​	$	20,832

X

- Definition

Tabular disclosure of depreciation and amortization.

+ References

No definition available.

+ Details

Name:	pahc_ScheduleOfDepreciationAndAmortizationTableTextBlock
Namespace Prefix:	pahc_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of interest expense, net.

+ References

No definition available.

+ Details

Name:	pahc_ScheduleOfInterestExpenseNetTableTextBlock
Namespace Prefix:	pahc_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of research and development expense.

+ References

No definition available.

+ Details

Name:	pahc_ScheduleOfResearchAndDevelopmentExpenseTableTextBlock
Namespace Prefix:	pahc_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_IncomeStatementRelatedDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:	us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration